{"nctId":"NCT00247273","briefTitle":"A Study of Monthly Risedronate for Osteoporosis","startDateStruct":{"date":"2005-10"},"conditions":["Postmenopausal Osteoporosis"],"count":1294,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: risedronate"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: risedronate"]}],"interventions":[{"name":"risedronate","otherNames":[]},{"name":"risedronate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female: 50 years of age or older\n* \\>5 years since last menses natural or surgical\n* have lumbar spine BMD (bone mineral density) more that 2.5 standard deviations (SD) below the young adult mean, or have 1-spine BMD more than 2.0 SD below the young adult female mean value and also have at least one prevalent vertebral body fracture\n\nExclusion Criteria:\n\n* history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia\n* BMI (body mass index) \\>32 kg/m\\^2\n* use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone\n* hypocalcemia or hypercalcemia of any cause\n* markedly abnormal clinical laboratory measurements that are assessed as clinically significant by the investigator","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population","description":"BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 12).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.425","spread":null},{"groupId":"OG001","value":"3.540","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population","description":"BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.522","spread":null},{"groupId":"OG001","value":"3.598","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population","description":"BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0256","spread":null},{"groupId":"OG001","value":"0.0261","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine BMD at Month 24-Endpoint, Endpoint Population (Month 24)","description":"BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 24).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.927","spread":null},{"groupId":"OG001","value":"4.166","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population","description":"BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.217","spread":null},{"groupId":"OG001","value":"4.302","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population","description":"BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0309","spread":null},{"groupId":"OG001","value":"0.0319","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urine Type-1 Collagen Cross-linked-N-telopeptide Corrected for Creatinine Clearance (NTX/Cr) at Month 6, ITT Population","description":"Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \\& 24. nmol BCE / mmol Creatinine = nanomoles bone collagen equivalents / millimoles Creatinine","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.04","spread":null},{"groupId":"OG001","value":"-30.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Urine NTX/Cr at Month 6, ITT Population","description":"Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \\& 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.83","spread":null},{"groupId":"OG001","value":"-50.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urine NTX/Cr at Month 24, ITT Population","description":"Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \\& 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.88","spread":null},{"groupId":"OG001","value":"-29.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Urine NTX/Cr at Month 24, ITT Population","description":"Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 \\& 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.45","spread":null},{"groupId":"OG001","value":"-46.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Type-1 Collagen Cross-linked C-telopeptide (CTX) at Month 6, ITT Population","description":"ng / mL = nanograms / milliliter. Assayed by electrochemiluminescent immunoassay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":null},{"groupId":"OG001","value":"-0.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum CTX at Month 6, ITT Population","description":"Assayed by electrochemiluminescent immunoassay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.79","spread":null},{"groupId":"OG001","value":"-53.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum CTX at Month 24, ITT Population","description":"Assayed by electrochemiluminescent immunoassay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":null},{"groupId":"OG001","value":"-0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum CTX at Month 24, ITT Population","description":"Assayed by electrochemiluminescent immunoassay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.33","spread":null},{"groupId":"OG001","value":"-23.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Bone-specific Alkaline Phosphatase (BAP) at Month 6, ITT Population","description":"ug / L = micrograms per liter, Assayed by ELISA (enzyme-linked immunosorbent assay)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.31","spread":null},{"groupId":"OG001","value":"-5.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum BAP at Month 6, ITT Population","description":"Assayed by ELISA (enzyme-linked immunosorbent assay)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.34","spread":null},{"groupId":"OG001","value":"-34.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum BAP at Month 24, ITT Population","description":"Assayed by ELISA (enzyme-linked immunosorbent assay)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.10","spread":null},{"groupId":"OG001","value":"-4.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum BAP at Month 24, ITT Population","description":"Assayed by ELISA (enzyme-linked immunosorbent assay)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.84","spread":null},{"groupId":"OG001","value":"-25.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New Vertebral Fracture at Month 12, ITT Population","description":"At least 1 new fractured vertebra","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New Vertebral Fracture at Month 24, ITT Population","description":"At least 1 new fractured vertebra","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":51,"n":642},"commonTop":["Influenza","Back Pain","Arthralgia","Nasopharyngitis","Bronchitis"]}}}